Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00103155
Recruitment Status : Unknown
Verified August 2005 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : February 8, 2005
Last Update Posted : September 20, 2013
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

February 7, 2005
February 8, 2005
September 20, 2013
September 2004
Not Provided
Frequency of radiofrequency ablation-associated complications at 2 weeks
Not Provided
Complete list of historical versions of study NCT00103155 on Archive Site
Amount of tumor destruction at 2 weeks
Not Provided
Not Provided
Not Provided
Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer
Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study

RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Ultrasound-guided radiofrequency ablation may be effective treatment for thyroid cancer.

PURPOSE: This phase I trial is studying the side effects of radiofrequency ablation in treating patients who are undergoing surgery for thyroid cancer.


  • Determine the frequency of complications associated with radiofrequency ablation (RFA) in patients with low-risk papillary thyroid cancer undergoing thyroidectomy.
  • Determine the utility of RFA as a treatment option for these patients.

OUTLINE: This is a pilot study.

An electrosurgical probe is placed by ultrasound guidance into the center of the thyroid tumor. Patients undergo radiofrequency ablation directly to the tumor until the target temperature is reached* for 5 minutes. Patients then undergo standard thyroidectomy.

NOTE: *Takes approximately 15-30 minutes to reach target temperature.

After completion of study treatment, patients are followed at day 1, between days 14-21, and then periodically as deemed necessary.

PROJECTED ACCRUAL: A total of 15-40 patients will be accrued for this study.

Phase 1
Primary Purpose: Treatment
Head and Neck Cancer
  • Procedure: conventional surgery
  • Procedure: radiofrequency ablation
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Not Provided
Not Provided
Not Provided
Not Provided


  • Cytologically confirmed papillary thyroid cancer by fine needle aspiration

    • Low-risk disease
    • No poorly differentiated cytology
  • Intrathyroidal tumor

    • Located within the anterior two-thirds of the thyroid lobe
    • Tumor not adjacent to the trachea by neck ultrasound
  • Tumor ≤ 1.5 cm by neck ultrasound
  • Requires thyroidectomy
  • No cervical lymphadenopathy
  • No multicentric tumors by neck ultrasound
  • No evidence of lymph node metastasis



  • Over 21

Performance status

  • Not specified

Life expectancy

  • Not specified


  • Not specified


  • Not specified


  • Not specified


Biologic therapy

  • Not specified


  • Not specified

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified
Sexes Eligible for Study: All
21 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
University of California, San Francisco
National Cancer Institute (NCI)
Study Chair: Electron Kebebew, MD University of California, San Francisco
National Cancer Institute (NCI)
August 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP